AbbVie Migraine Career Catalyst Awardtm contest winners shared inspiring stories and professional goals, showcasing their triumphs over the challenges of living with migraine AbbVie, a leader in ...

The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

I last wrote on AbbVie Inc. (NYSE:ABBV) back in September 2024 and on Pfizer Inc. (NYSE:PFE) back in August 2024. These articles are titled “AbbVie: Dividend Discount Model Suggests Large ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

A splashy recent acquisition by the company might not be panning out. Just before the market open on Monday, AbbVie revealed that its emraclidine schizophrenia treatment did not meet its primary ...

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.

An AbbVie schizophrenia drug acquired as part of a multi-billion dollar deal has failed two mid-stage studies, dealing a setback to the company’s plans to compete with a Bristol Myers Squibb ...

Neuroscience is a key area of focus for AbbVie. In addition to emraclidine, through the Cerevel acquisition AbbVie gained a neuroscience pipeline of multiple clinical-stage and preclinical ...

For AbbVie, the good news this week is that the failure of a high-profile schizophrenia drug in two key trials hardly marks its last opportunity to make strides in neuroscience. The bad news is ...

according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. AbbVie Inc (Symbol ...